NVS logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
Next Earnings Report
Feb 3, 2027
EPS est. $2.23 · Revenue est. $14.69B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Mar 17, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (44)

Dec 2026
Est. completion
Multiple Sclerosis
DreaMS - Validation Study 1
Dec 2026
Est. completion
P2Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Dec 2026
Est. completion
P1Elevated Blood Pressure
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension
Dec 2026
Est. completion
Multiple Sclerosis
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
Dec 2026
Est. completion
NAType 2 Diabetes
E3 Diabetes - Closing the Gap in Diabetes Control
Feb 2027
Est. completion
P1P2Advanced Soft-tissue Sarcoma
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
Feb 2027
Est. completion
P1P2Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Apr 2027
Est. completion
P4Coronary Heart Disease
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
May 2027
Est. completion
P4Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Jul 2027
Est. completion
P3Ovarian Neoplasm Epithelial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Aug 2027
Est. completion
Hypertension
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Sep 2027
Est. completion
P2Cancer
The Drug Rediscovery Protocol (DRUP Trial)
Dec 2027
Est. completion
Advanced Breast Cancer
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Feb 2028
Est. completion
Melanoma
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Apr 2028
Est. completion
P3IgA Nephropathy
Atrasentan in Patients With IgA Nephropathy
Jun 2028
Est. completion
P2Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Jun 2028
Est. completion
P1Advanced Malignancies and Hepatic Impairment
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Jul 2028
Est. completion
P1P2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Aug 2028
Est. completion
P1Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Sep 2028
Est. completion
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Awaiting Results (12)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
National Register of Actionable Mutations
NCT05918666
Oct 2026
P1
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217
Oct 2026
P1P2
Ribociclib and Bicalutamide in AR+ TNBC
NCT03090165
Jul 2026
P1
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
NCT05469360
Jul 2026
P1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT07340138
Feb 2026
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801
Aug 2025
P2
Eltrombopag for Fanconi Anemia
NCT03206086
Nov 2024
P2
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843
Jan 2024
P2
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02881242
Jul 2023
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT04497285

SEC Filings (61)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 4, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Jul 21, 20266-KForeign issuer reportDocumentIndex
Jun 11, 20266-KForeign issuer reportDocumentIndex
Apr 28, 20266-KForeign issuer reportDocumentIndex
Mar 18, 20266-KForeign issuer reportDocumentIndex
Mar 17, 2026424B5Offering prospectusDocumentIndex
Mar 17, 2026FWPDocumentIndex
Mar 16, 2026424B5Offering prospectusDocumentIndex
Feb 4, 2026S-8Employee stock planDocumentIndex
Feb 4, 20266-KForeign issuer reportDocumentIndex
Feb 4, 20266-KForeign issuer reportDocumentIndex
Feb 4, 2026IRANNOTICEDocumentIndex
Feb 4, 202620-FAnnual report (foreign)DocumentIndex
Jan 16, 2026S-8 POSEmployee stock planDocumentIndex
Jan 16, 2026S-8 POSEmployee stock planDocumentIndex
Jan 16, 2026S-8 POSEmployee stock planDocumentIndex
Jan 16, 2026S-8 POSEmployee stock planDocumentIndex
Jan 14, 2026DFAN14ADocumentIndex
Jan 12, 2026DFAN14ADocumentIndex
Nov 25, 20256-KForeign issuer reportDocumentIndex
Nov 20, 20256-KForeign issuer reportDocumentIndex
Nov 5, 20256-KForeign issuer reportDocumentIndex
Nov 4, 2025424B5Offering prospectusDocumentIndex
Nov 4, 2025FWPDocumentIndex
Nov 3, 2025424B5Offering prospectusDocumentIndex
Oct 28, 2025DFAN14ADocumentIndex
Oct 28, 2025SC TO-T/ATender offerDocumentIndex
Oct 28, 2025DFAN14ADocumentIndex
Oct 28, 20256-KForeign issuer reportDocumentIndex
Oct 27, 2025DFAN14ADocumentIndex
Oct 27, 2025DFAN14ADocumentIndex
Oct 27, 2025DFAN14ADocumentIndex
Oct 27, 20256-KForeign issuer reportDocumentIndex
Oct 22, 2025SC TO-T/ATender offerDocumentIndex
Sep 30, 20256-KForeign issuer reportDocumentIndex
Sep 29, 2025SC TO-TTender offerDocumentIndex